Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Outcomes of Ibrutinib Plus Venetoclax in Patients With Chronic Lymphocytic Leukemia in Routine Clinical Practice

NCT07774390 is registered in ClinicalTrials.gov with European Research Initiative on CLL as lead sponsor.

NCT NCT07774390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Outcomes of Ibrutinib Plus Venetoclax in Patients With Chronic Lymphocytic Leukemia in Routine Clinical Practice
Lead sponsor
European Research Initiative on CLL
Phase
Observational
Overall status
Recruiting
Start date
December 18, 2025
Completion date
November 20, 2034
Enrollment
323 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll)